Lucid Diagnostics Inc. (LUCD) Stock Price & Analysis

Lucid Diagnostics Inc. (LUCD) rose 3.28% to USD 0.99 as of June 10, 2026 at 07:04 UTC, according to Nexqual real-time market data.

LUCD last closed at USD 0.96; the session ranged USD 0.97–1.02 on volume of 1,080,781 shares. Market capitalization is $188.77M, with a 52-week range of USD 0.9–1.63 (NCM). Source: Nexqual, June 10, 2026 at 07:04 UTC.

Key Statistics (as of June 10, 2026 at 07:04 UTC)

Technical Analysis (LUCD)

Nexqual's technical model rates LUCD "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:04 UTC.

Analyst Ratings (LUCD)

Wall Street analysts rate LUCD "Strong Buy" based on 5 analysts, with a mean price target of USD 3.95 (range USD 2–9.25), per Nexqual as of June 10, 2026 at 07:04 UTC.

Earnings (LUCD)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 07:04 UTC.

Financials & Fundamentals (LUCD)

Source: Nexqual, June 10, 2026 at 07:04 UTC.

Financial Health Score (LUCD)

Nexqual rates Lucid Diagnostics Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:04 UTC.

Ownership (LUCD)

Source: Nexqual, June 10, 2026 at 07:04 UTC.

Leadership (LUCD)

Lucid Diagnostics Inc. is led by Lishan Aklog (age 59), Chairman & CEO, per Nexqual as of June 10, 2026 at 07:04 UTC.

Major Backers & Investors (LUCD)

Notable institutional backers of Lucid Diagnostics Inc. include Masters Capital Management, LLC, Aberdeen Group plc, abrdn Healthcare Opportunities Fund, according to Nexqual as of June 10, 2026 at 07:04 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 07:04 UTC.

From Lucid Diagnostics Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Subsequent to December 31, 2025, as of March 23, 2026, the Company sold 4,161,747 shares through its at-the-market equity facility for net proceeds of approximately $5.3 million, after payment of 3% commissions.   8 Table of Contents Intellectual Property   Our business will depend on proprietary medical device and diagnostic technologies, including the EsoCheck and EsoGuard technology licensed by us.
• Pursuant to this designa tion, we will be working with FDA to submit the premarket submission for EsoGuard.   Before and after approval or clearance in the United States, our products are subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act and/or the Public Health Service Act, as well as by other regulatory bodies.
• We intend to vigorously protect our proprietary technologies' intellectual property rights in patents, trademarks and copyrights, as available through registration in the United States and internationally.
• We protect our proprietary rights through a variety of methods, including confidentiality agreements and/or proprietary information agreements with suppliers, employees, consultants, independent contractors and other entities who may have access to proprietary information.

Partnerships

• PAVmed's substantial voting interest may discourage a change of control that other holders of our common stock may favor.   We are party to a management services agreement with PAVmed (the "MSA"), as well as a payroll benefits and expense reimbursement agreement (the "PBERA").
• The Company intends to use the net proceeds from the September 2025 Offering for working capital and other general corporate purposes.   ATM Facility        On May 30, 2025, the Company entered into an "at-the-market offering" ("ATM") for up to $25.0 million of its common stock that may be offered and sold under a Controlled Equity Offering Agreement between the Company and Maxim Group LLC.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:04 UTC. This page is informational and not investment advice.